Advanced Search: Relapsed/Refractory

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

202012066

A PHASE Ib /II STUDY OF APG-115 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMAS OR ADVANCED SOLID TUMORS

202101200

Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma

202102173

A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients with Advanced Solid Tumors

202105158

A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

202105163

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects with Previously Treated Soft-Tissue Sarcomas With Pulmonary Metastases

202107082

A phase II trial with a safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma

202112086

A dose escalation and dose expansion study of NOX66 plus doxorubicin in anthracycline-naïve, adult patients with soft tissue sarcoma - CEP-2